financetom
Business
financetom
/
Business
/
ServiceNow 'Well-positioned' to Sustain 20% Subscription Growth, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ServiceNow 'Well-positioned' to Sustain 20% Subscription Growth, Morgan Stanley Says
Sep 24, 2025 7:20 AM

10:08 AM EDT, 09/24/2025 (MT Newswires) -- ServiceNow ( NOW ) is "well-positioned" to sustain a 20% subscription increase and drive more than 20% free cash flow growth through fiscal 2027, analysts at Morgan Stanley said in a note Wednesday.

ServiceNow's ( NOW ) overall business fundamentals have remained sound despite a volatile backdrop, delivering subscription revenue growth of about 20%, an operating margin percentage of between high-20s to low-30s, and "solid" free cash flow growth, analysts said.

"ServiceNow's ( NOW ) execution has remained encouraging and while GenAI and federal-related uncertainties are understandable, we view both as overblown and believe the company is well-positioned to execute upon a robust agentic AI opportunity and a more reasonable 2026 setup," analysts said.

Analysts upgrade the stock to overweight and raise its price target to $1,250 from $1,040.

Shares of the company were up over 2% in recent Wednesday trading.

Price: 952.59, Change: +24.92, Percent Change: +2.69

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nukkleus Stock Soars To Fresh Highs On Tiltan Defense Tech Deal
Nukkleus Stock Soars To Fresh Highs On Tiltan Defense Tech Deal
Sep 2, 2025
Nukkleus Inc. ( NUKK ) shares soared on Tuesday after the company said it will acquire Israel-based Tiltan Software Engineering Ltd. in a $14 million deal. The acquisition, to be paid in a mix of cash and stock, is expected to close following regulatory approval and audited financials. The announcement underscores growing demand for AI-powered simulation and GPS-denied navigation tools...
Blue Bird Insider Sold Shares Worth $767,260, According to a Recent SEC Filing
Blue Bird Insider Sold Shares Worth $767,260, According to a Recent SEC Filing
Sep 2, 2025
11:25 AM EDT, 09/02/2025 (MT Newswires) -- Phil Horlock, Director, on August 28, 2025, sold 13,000 shares in Blue Bird ( BLBD ) for $767,260. Following the Form 4 filing with the SEC, Horlock has control over a total of 240,766 common shares of the company, with 240,766 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1589526/000157947725000018/xslF345X05/wk-form4_1756826178.xml Price: 57.75, Change: -0.64, Percent Change:...
Update: Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia
Update: Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia
Sep 2, 2025
11:26 AM EDT, 09/02/2025 (MT Newswires) -- (Updates with recent stock movement in the headline and first paragraph.) Ionis Pharmaceuticals ( IONS ) shares were up more than 33% in recent Tuesday trading after the company reported topline data from phase 3 studies of olezarsen, which showed that the drug candidate significantly reduced fasting triglycerides and acute pancreatitis events in...
Update: Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced
Update: Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced
Sep 2, 2025
11:25 AM EDT, 09/02/2025 (MT Newswires) -- (Updates to include Arrowhead's stock movement in the headline and the first paragraph.) Arrowhead Pharmaceuticals ( ARWR ) shares rose 9.2% in recent Tuesday trading after the company announced a global licensing and collaboration agreement for its ARO-SNCA preclinical stage siRNA therapy to treat synucleinopathies, including Parkinson's disease, with Novartis ( NVS )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved